{"id":387123,"date":"2020-11-23T16:08:10","date_gmt":"2020-11-23T21:08:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387123"},"modified":"2020-11-23T16:08:10","modified_gmt":"2020-11-23T21:08:10","slug":"neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/","title":{"rendered":"Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol"},"content":{"rendered":"

\nTouchStar theta burst protocol leverages NeuroStar\u00ae Advanced Therapy\u2019s patented Contact Sensing technology to help ensure the optimum prescribed treatment dose to patients
\n<\/h2>\n
\n

MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced the U.S. Food and Drug Administration (FDA) granted clearance for the Company\u2019s TouchStar treatment, a three-minute intermittent theta burst (iTBS) protocol with its NeuroStar Advanced Therapy System, administered with patented Contact Sensing technology.<\/p>\n

The new protocol arms physicians with the ability to now offer a third FDA-cleared treatment protocol with NeuroStar Advanced Therapy \u2013 a non-drug, non-invasive transcranial magnetic stimulation (TMS) treatment for Major Depressive Disorder (MDD) that uses magnetic pulses to stimulate areas of the brain that are underactive in depression. The three-minute TouchStar protocol allows clinicians to further customize treatments to best suit patient needs while increasing utilization of the NeuroStar Advanced Therapy System and expanding its benefits to more patients.<\/p>\n

TouchStar with Contact Sensing provides physicians and their patients with the option of shorter treatment sessions using higher frequency pulses while helping ensure that the proper dose is being given at every session. The Contact Sensing technology monitors NeuroStar Advanced Therapy\u2019s contoured coil, which is designed with a curve to fit the head and provides continuous real-time feedback about the coil\u2019s angle and contact with the head.<\/p>\n

\u201cThe TouchStar protocol is particularly impactful when paired with our patented Contact Sensing precision technology that provides clinicians with the confidence of knowing they are giving patients the right dose at the exact location,\u201d said Greg Harper, Vice President of Product Development and Operations at Neuronetics. \u201cA faster solution to target depression is certainly a benefit, but when we\u2019re shortening those treatment times it is even more critical that proper coil position is maintained. With TMS systems, if coil contact with the head is off by just 1mm, up to 40 percent of the required dosage can be lost1<\/sup> \u2013 Contact Sensing monitors coil position and helps ensure patients get the full prescribed treatment dosage every session.\u201d<\/p>\n

TouchStar is the latest advancement designed to enhance treatment options and expand access and availability of NeuroStar Advanced Therapy for patients. The system now has three treatment variations: standard, which offers treatments at 37.5 minutes per session; DASH, which offers treatments as little as 19 minutes per session; and TouchStar, which offers treatments at three minutes per session. TouchStar will be available to NeuroStar providers in the first quarter of 2021.<\/p>\n

\u201cTouchStar protocol clearance is an especially relevant milestone as depression rates continue to rise and providing access to proven depression treatments remains more critical than ever before,\u201d said Keith J. Sullivan, President and CEO of Neuronetics. \u201cOur hope is that this third treatment protocol will mean even more patients in need will have access to NeuroStar Advanced Therapy to help them in their battle with this debilitating disease.\u201d<\/p>\n

Neuronetics remains committed to gathering real world outcomes for treatment through the NeuroStar Outcomes Registry and will include TouchStar data as part of the largest outcomes registry in the world for MDD. Visit www.neurostar.com<\/a> for more information.<\/p>\n

\n About Neuronetics<\/strong>
\n
Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its commercial product, the NeuroStar\u00ae Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan\u2019s national health insurance. Additional information can be found at www.neuronetics.com<\/a>.<\/p>\n

\n Media Contact: <\/strong>
\n
Meagan Dominick
Vault Communications
610-455-2779
mdominick@vaultcommunications.com<\/a><\/p>\n

\n 1<\/sup> Data on file. Neuronetics, Inc.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

TouchStar theta burst protocol leverages NeuroStar\u00ae Advanced Therapy\u2019s patented Contact Sensing technology to help ensure the optimum prescribed treatment dose to patients MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced the U.S. Food and Drug Administration (FDA) granted clearance for the Company\u2019s TouchStar treatment, a three-minute intermittent theta burst (iTBS) protocol with its NeuroStar Advanced Therapy System, administered with patented Contact Sensing technology. The new protocol arms physicians with the ability to now offer a third FDA-cleared treatment protocol with NeuroStar Advanced Therapy \u2013 a non-drug, non-invasive transcranial magnetic … <\/p>\n

Continue reading “Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-387123","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TouchStar theta burst protocol leverages NeuroStar\u00ae Advanced Therapy\u2019s patented Contact Sensing technology to help ensure the optimum prescribed treatment dose to patients MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced the U.S. Food and Drug Administration (FDA) granted clearance for the Company\u2019s TouchStar treatment, a three-minute intermittent theta burst (iTBS) protocol with its NeuroStar Advanced Therapy System, administered with patented Contact Sensing technology. The new protocol arms physicians with the ability to now offer a third FDA-cleared treatment protocol with NeuroStar Advanced Therapy \u2013 a non-drug, non-invasive transcranial magnetic … Continue reading "Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T21:08:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTA1MyMzODQwODE5IzIxMTA0NDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol\",\"datePublished\":\"2020-11-23T21:08:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\\\/\"},\"wordCount\":702,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTA1MyMzODQwODE5IzIxMTA0NDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\\\/\",\"name\":\"Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTA1MyMzODQwODE5IzIxMTA0NDA=\",\"datePublished\":\"2020-11-23T21:08:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTA1MyMzODQwODE5IzIxMTA0NDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTA1MyMzODQwODE5IzIxMTA0NDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/","og_locale":"en_US","og_type":"article","og_title":"Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol - Market Newsdesk","og_description":"TouchStar theta burst protocol leverages NeuroStar\u00ae Advanced Therapy\u2019s patented Contact Sensing technology to help ensure the optimum prescribed treatment dose to patients MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced the U.S. Food and Drug Administration (FDA) granted clearance for the Company\u2019s TouchStar treatment, a three-minute intermittent theta burst (iTBS) protocol with its NeuroStar Advanced Therapy System, administered with patented Contact Sensing technology. The new protocol arms physicians with the ability to now offer a third FDA-cleared treatment protocol with NeuroStar Advanced Therapy \u2013 a non-drug, non-invasive transcranial magnetic … Continue reading \"Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T21:08:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTA1MyMzODQwODE5IzIxMTA0NDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol","datePublished":"2020-11-23T21:08:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/"},"wordCount":702,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTA1MyMzODQwODE5IzIxMTA0NDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/","name":"Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTA1MyMzODQwODE5IzIxMTA0NDA=","datePublished":"2020-11-23T21:08:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTA1MyMzODQwODE5IzIxMTA0NDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTA1MyMzODQwODE5IzIxMTA0NDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neuronetics\u00ae Receives FDA Clearance for Three-Minute TouchStar\u2122 Treatment Protocol"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=387123"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387123\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=387123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=387123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=387123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}